Abstract 1956P
Background
Alternative promoters and splice sites enable most human genes to generate multiple transcript isoforms, significantly increasing phenotypic complexity. Large-scale tumor RNA-seq analysis has demonstrated widespread splicing aberrations and alternative promoter activation in cancer, implicating isoform dysregulation as a crucial factor in carcinogenesis.
Methods
By integrating RNA-seq data from TCGA, PCAWG, and GTEx projects, we reconstructed individual transcript sequences expressed in more than 26000 cancer and normal samples, elucidating a comprehensive panorama of alternative isoform utilization across 39 tissues and 38 cancer types.
Results
Our isoform-centric analysis reveals that (1) global transcriptome architecture is distinct across tissues, between cancer and normal samples of the same tissue origin, and between cancer molecular subtypes—even at sub-gene resolution; (2) alternative promoter usage and splicing together contribute to ∼40% of transcriptome heterogeneity across tissues and 50-60% within tissues and cancer types; (3) cancer frequently increases the usage of aberrant tumor suppressor gene isoforms lacking protein-coding potential; (4) differentially used isoforms hold significant prognostic value in various cancers, with aberrant transcripts from NRG1, CAMTA1, and LRP1B demonstrating the strongest association with survival; and (5) co-occurring differential splicing events within single RNA molecules may offset each other's frame-shifting effects.
Conclusions
Our findings indicate cancer frequently dysregulates alternative isoform usage, perturbing key oncogenic pathways. This highlights the value of isoform-resolution transcriptome profiling for improved individualized cancer diagnostics and treatment strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Korea Advanced Institute of Science and Technology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Assessing response durability and survival after second-line pembrolizumab in advanced urothelial carcinoma: A multicenter validation of a risk model
Presenter: Samer Salah
Session: Poster session 13
2010P - Trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for high and intermediate risk non muscle invasive bladder cancer (HMR-NMIBC): Interim analysis of a phase I study
Presenter: Aleksander Antoniewicz
Session: Poster session 13
2011P - Neoadjuvant immunotherapy-driven bladder preservation for muscle-invasive bladder cancer: A multicenter, propensity score-matched cohort study
Presenter: Jiao Hu
Session: Poster session 13
2012P - Role of first-line immunotherapy in urothelial cancer with bone metastases: A national cancer database analysis of 3971 patients
Presenter: Zin Myint
Session: Poster session 13
2013P - First preliminary results of artificial intelligence generated treatment recommendations for urothelial cancer based on multidisciplinary cancer conferences from the KITTU project
Presenter: Gregor Duwe
Session: Poster session 13
2014P - Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA)
Presenter: Patrizia Giannatempo
Session: Poster session 13
2015P - Serum nectin-4: Prognostic and predictive value in bladder cancer?
Presenter: Kerstin Junker
Session: Poster session 13
2016P - Evaluation of event-free survival (EFS) as a surrogate endpoint for overall survival (OS) in muscle-invasive bladder cancer (MIBC) following neoadjuvant (NAD) therapy
Presenter: Cora Sternberg
Session: Poster session 13
2017P - Intrinsic molecular difference between bladder and upper tract urothelial carcinomas and its impacts in treatment response
Presenter: Jiwon Kim
Session: Poster session 13